PGT-A is a laboratory test used with IVF to assess whether sampled cells from an embryo show the expected number of chromosomes. It may help a clinical team prioritise among available embryos in selected circumstances. It does not ensure implantation, pregnancy, a healthy baby or a particular IVF outcome.
The test is often compressed into phrases that sound more certain than the evidence. A responsible discussion separates what is measured, what is inferred and what remains unknown. It also explains that PGT-A is not the same as testing for a known single-gene condition in a family.
What PGT-A examines
Human cells usually contain chromosomes in expected pairs. An embryo with an extra or missing chromosome is described as aneuploid. PGT-A assesses chromosome number in a small sample of cells taken from the part of a blastocyst expected to contribute to the placenta.
The result helps the team discuss which embryo may be considered for transfer. It is a screening result rather than a complete diagnosis of every cell in the embryo. The sampled cells may not always represent the rest of the embryo, and laboratories may report categories such as euploid, aneuploid, mosaic or inconclusive according to validated methods and policy.
PGT-A does not test for all genetic conditions, birth differences, developmental conditions or causes of miscarriage. It does not replace recommended prenatal screening or diagnostic discussions if pregnancy occurs.
PGT-A and testing for an inherited disorder are different
When a person or couple has a known risk of a specific inherited single-gene condition, a different test—commonly called PGT-M—may be discussed. That pathway usually requires specialist genetic counselling, confirmation of the familial variant and development of a condition-specific testing plan.
PGT-A, by contrast, assesses chromosome number. One test cannot be assumed to perform the job of the other. In some medically indicated cycles, different forms of testing may be considered together, but the indication, consent, limits and interpretation should be explained separately.
If an inherited condition is part of your history, do not rely on a general PGT-A package description. Ask for a referral to an appropriately qualified genetics professional and a written explanation of exactly what the proposed test can detect.
Where PGT-A fits into an IVF cycle
PGT-A cannot be done as a stand-alone blood test. It is part of an IVF and embryo-laboratory pathway:
- The ovaries are stimulated and eggs are collected.
- Mature eggs are fertilised through IVF or ICSI as clinically planned.
- Embryos are cultured to the stage at which biopsy may be possible.
- A few cells are carefully removed by a trained embryology team.
- Embryos are commonly vitrified while the sample is analysed.
- Results are reviewed before a later transfer plan is made.
Not every collected egg becomes an embryo, and not every embryo reaches a stage suitable for biopsy. A biopsy can yield an inconclusive result. Testing can therefore leave fewer embryos available for transfer, and it introduces additional procedures, time and cost.
Read the IVF treatment process and embryo freezing guide to understand the clinical and storage stages surrounding the test.
What the evidence does and does not show
PGT-A may help identify embryos with an expected chromosome number and may reduce transfers that are less likely to implant. For some people, that may improve efficiency per transfer or reduce the likelihood of miscarriage associated with aneuploidy. These possible benefits are not the same as improving the overall chance of a baby from all embryos created in a cycle.
Evidence and relevance differ by patient group. The UK fertility regulator’s current patient guidance rates PGT-A differently depending on the outcome being considered: it does not support routine use to improve the chance of a baby for most fertility patients, while finding evidence of reduced miscarriage for many patients. It advises individual consideration based on circumstances and history.
This is why a clinic should not present PGT-A as a standard upgrade. Ask which outcome the specialist is trying to change, whether evidence applies to people with your characteristics, and whether testing could reduce the number of embryos available.
Limitations and risks to discuss
Embryo biopsy is a skilled laboratory procedure. Embryos can continue to develop after cells are removed, but there is a possibility of damage. Freezing and warming also form part of the pathway. No laboratory can make uncertainty disappear.
Mosaic findings can be especially complex because the sample contains a mixture of cells with different chromosome findings. Policies for reporting, counselling, storage and possible transfer can differ. These results require specialist interpretation rather than a simple suitable-or-unsuitable label.
Ask about:
- the exact medical indication being considered;
- which laboratory performs the test and how results are reported;
- the possibility of an inconclusive or mosaic result;
- the biopsy, freezing and warming process;
- what happens if no embryo is suitable for biopsy or prioritised for transfer;
- whether genetic counselling is available before and after testing; and
- why prenatal testing may still be discussed after pregnancy.
Medical use and Indian legal safeguards
Fertility treatment and genetic testing in India must operate within the Assisted Reproductive Technology framework and the Pre-Conception and Pre-Natal Diagnostic Techniques law. The appropriate purpose is medical assessment under current law, with informed consent and professional counselling.
You can read the official PCPNDT Act on India Code and the Assisted Reproductive Technology (Regulation) Act, 2021. Legal requirements and laboratory practice can change, so a clinic should confirm the prevailing rules that apply at the time of treatment.
Questions for a PGT-A consultation
Start by asking, “What medical question are we trying to answer?” Then ask whether PGT-A is being considered because of age, embryo history, pregnancy history or another individual factor. Request an explanation of the evidence for your patient group, not a general claim about tested embryos.
Discuss how many embryos might reasonably reach biopsy based on the information available, while recognising that this cannot be known before a cycle. Ask how the clinic would counsel you if there were no result, a mosaic result or no embryo prioritised for transfer. Obtain an itemised estimate covering biopsy, testing, freezing, storage and a future frozen transfer.
Most importantly, confirm that declining PGT-A does not remove your right to respectful discussion of standard IVF options. Informed consent includes understanding alternatives and having time to decide.
For a focused overview, visit PGT-A genetic screening at Umeed IVF. To request a medically appropriate consultation in Delhi, contact Umeed IVF. This article cannot determine whether testing is suitable for a particular embryo or treatment cycle.
Sources and further reading
- PGT-A treatment-add-on guidance — Human Fertilisation and Embryology Authority
- PGT-A committee opinion, 2024 — American Society for Reproductive Medicine
- PCPNDT Act — India Code
- Assisted Reproductive Technology (Regulation) Act, 2021 — India Code